Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Toronto Stock Exchange  >  Bausch Health Companies Inc    BHC   CA0717341071

BAUSCH HEALTH COMPANIES INC

(BHC)
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsAnalyst Recommendations

Bausch Health : Court Upholds The Validity And Determined Actavis' Infringement Of Patent Protecting RELISTOR® Tablets

share with twitter share with LinkedIn share with facebook
share via e-mail
0
07/17/2019 | 07:43pm EDT

BRIDGEWATER, N.J. and NEW YORK, July 17, 2019 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health" or the "Company") and Progenics Pharmaceuticals (NASDAQ: PGNX), announced today that the U.S. District Court of New Jersey upheld the validity and determined Actavis' infringement of a patent protecting RELISTOR® (methylnaltrexone bromide) tablets, expiring March 2031.

Defendant, Actavis Laboratories FL, Inc., a subsidiary of Teva Pharmaceutical Industries Ltd, had challenged the validity of and had alleged non-infringement of Claims 2 and 5 of U.S. Patent No. 8,524,276, which protects the formulation of RELISTOR® tablets.

Bausch Health is not aware of any other ANDAs filed with the FDA seeking approval of a generic version of RELISTOR tablets, and will continue to vigorously defend its intellectual property in these and other claims.

About Progenics
Progenics is an oncology company focused on the development and commercialization of innovative targeted medicines and artificial intelligence to find, fight and follow cancer, including: therapeutic agents designed to treat cancer (AZEDRA®, 1095, and PSMA TTC); prostate-specific membrane antigen ("PSMA") targeted imaging agents for prostate cancer (PyL™ and 1404); and imaging analysis technology (aBSI and PSMA AI). Progenics has two commercial products, AZEDRA, for the treatment of patients with unresectable, locally advanced or metastatic pheochromocytoma or paraganglioma (rare neuroendocrine tumors of neural crest origin) who require systemic anticancer therapy; and RELISTOR® (methylnaltrexone bromide) for the treatment of opioid-induced constipation, which is partnered with Bausch Health Companies Inc.

About Bausch Health
Bausch Health Companies Inc. (NYSE/TSX: BHC) is a global company whose mission is to improve people's lives with our health care products. We develop, manufacture and market a range of pharmaceutical, medical device and over-the-counter products, primarily in the therapeutic areas of eye health, gastroenterology and dermatology. We are delivering on our commitments as we build an innovative company dedicated to advancing global health. More information can be found at www.bauschhealth.com.

Forward-looking Statements 
This news release may contain forward-looking statements, which may generally be identified by the use of the words "anticipates," "expects," "intends," "plans," "should," "could," "would," "may," "will," "believes," "estimates," "potential," "target," or "continue" and variations or similar expressions. These statements are based upon the current expectations and beliefs of management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include, but are not limited to, risks and uncertainties discussed in the Company's most recent annual or quarterly report and detailed from time to time in the Company's other filings with the Securities and Exchange Commission and the Canadian Securities Administrators, which factors are incorporated herein by reference. In addition, certain material factors and assumptions have been applied in making these forward-looking statements, including that the risks and uncertainties outlined above will not cause actual results or events to differ materially from those described in these forward-looking statements. The Company believes that the material factors and assumptions reflected in these forward-looking statements are reasonable, but readers are cautioned not to place undue reliance on any of these forward-looking statements. These forward-looking statements speak only as of the date hereof. Bausch Health undertakes no obligation to update any of these forward-looking statements to reflect events or circumstances after the date of this news release or to reflect actual outcomes, unless required by law.

Investor/Media Contact:
Arthur Shannon
arthur.shannon@bauschhealth.com
(514) 856-3855
(877) 281-6642 (toll free)

Bausch Health logo (PRNewsfoto/Bausch Health Companies Inc.)

Cision
View original content to download multimedia:http://www.prnewswire.com/news-releases/court-upholds-the-validity-and-determined-actavis-infringement-of-patent-protecting-relistor-tablets-300887079.html

SOURCE Bausch Health Companies Inc.


© PRNewswire 2019
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on BAUSCH HEALTH COMPANIES IN
08/07BAUSCH HEALTH : FDA Accepts NDA For IDP-123 Lotion for Acne
DJ
08/07BAUSCH HEALTH : Ortho Dermatologics Announces U.S. FDA Filing Acceptance For IDP..
AQ
08/06BAUSCH HEALTH : Management's Discussion and Analysis of Financial Condition and ..
AQ
08/06BAUSCH HEALTH : reports better Q2 results, raises 2019 estimated revenue, earnin..
AQ
08/06BAUSCH : 2Q Earnings Snapshot
AQ
08/06BAUSCH HEALTH : Increases Revenue, Adjusted Ebitda Guidance
DJ
08/06BAUSCH HEALTH : Loss Lessens As Expenses Fall
DJ
08/06BAUSCH HEALTH COMPANIES INC. : Results of Operations and Financial Condition (fo..
AQ
08/06BAUSCH HEALTH COMPANIES INC. : Announces Second-Quarter 2019 Results And Raises ..
PR
08/01BAUSCH HEALTH : + Lomb Initiates First Clinical For Technolas Teneo Excimer Lase..
AQ
More news